search
Back to results

Human Milk Oligosaccharide (HMO) Supplementation in Colic Management

Primary Purpose

Colic

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
HMO
Placebo
Parental reassurance and support
Sponsored by
Société des Produits Nestlé (SPN)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Colic

Eligibility Criteria

2 Weeks - 12 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Infants 2 weeks - 8 weeks of age at enrolment
  2. Infants diagnosed with colic according to Rome IV criteria: Diagnostic criteria for research purposes (infant must meet all Rome IV criteria):

    1. An infant who is less than 5 months of age (in the current clinical trial, only infants 2 weeks to 8 weeks of age will be enrolled) when the symptoms start and stop
    2. Recurrent and prolonged periods of infant crying, fussing, or irritability reported by caregivers that occur without obvious cause and cannot be prevented or resolved by caregivers
    3. No evidence of infant failure to thrive, fever, or illness
    4. Excessive crying/fussiness for 3 or more hours per day during 3 or more days in the past 7 days as reported by parents to the clinician
    5. Total 24-hour crying plus fussing is 3 hours or more when measured by at least one prospectively kept 24-hour behavior diary. (The Structured Infant Crying and Fussing Diary will be dispensed at the screening visit (V0), completed for two 24-hour periods at H0 (days -3 to -1), and returned at V1 to be used as part of the diagnostic criteria for infantile colic.)
  3. Term infants (≥ 37 weeks) generally healthy with normal birth weight (≥2.5kg) and singleton born
  4. Predominantly formula fed* (formula fed ≥ 80% of the time) for at least 7 days before randomization and the choice of formula feeding has been made by the parents before the beginning of the trial.
  5. Infants who have been on the same formula for the past 5 days
  6. Signed informed consent obtained for infant's and parents'/Legally Acceptable Representative (LAR) participation in the study
  7. Parent/LAR of infant agrees not to enroll infant in another interventional clinical research study while participating in this study
  8. Parent of the infant/LAR is willing and able to fulfill the requirements of the study protocol
  9. Parent of infant can be contacted throughout the study

    • Predominantly formula feeding defined in the study means that the infant's predominant source of nourishment is formula. Specifically, infants are fed with formula for at least 80% of total milk feeds per day.

Exclusion criteria:

  1. Presence of any congenital condition and/or previous or current illness/infection and (or) medication use that could interfere with the main study outcomes.
  2. Clinical evidence of chronic illness or gastrointestinal disorders, major medical problems (e.g. ill, immunocompromised, major developmental or genetic abnormality).
  3. Known cow's milk protein allergy, lactose intolerance, or galactosaemia; including presence of any allergic manifestations.
  4. Received any special formula (e.g. lactose-free, hydrolyzed protein) within 5 days before randomization or switched formulas within 5 days before randomization.
  5. Received any of the following products/medication within 5 days before randomization:

    1. Antibiotics
    2. Alginate
    3. Prokinetics
    4. Proton pump inhibitors
    5. Simethicone
    6. Colic remedies (herbal treatments or teas (such as fennel, vervain, licorice), chamomile, peppermint), glucose, sucrose, and lactase drops)
    7. L. reuteri probiotic
    8. Formula containing Human milk Oligosaccharides
  6. Other infant(s) <6months of age living in the same household.
  7. Current participation in another interventional clinical trial.

Sites / Locations

  • Ospedale Pediatrico Giovanni XXIII, Policlinico di BariRecruiting
  • ASST FBF SaccoRecruiting
  • AOUP Paolo GiacconeRecruiting
  • Azienda Ospedaliero -Universitaria PisanaRecruiting
  • Centro de Salud El RaneroRecruiting
  • Hospital Clínico Universitario de Santiago de CompostelaRecruiting
  • Unidad de Estudios e Investigación IHPRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Liquid oral supplement comprising HMO

Placebo

Arm Description

2 ampules/day for 21 days

2 ampules/day for 21 days

Outcomes

Primary Outcome Measures

Difference in average infant daily crying and fussing duration
Difference in average infant daily crying and fussing duration at the end of the intervention in the Intervention Group (IG) versus the Control Group (CG). The crying and fussing duration is measured using a structured infant crying and fussing diary.

Secondary Outcome Measures

Modulation of infant gut microbiota (communities of microbes, their taxonomy, strain composition, diversity, ecology, functionalities, and the metabolites produced)
Modulation of infant gut microbiota in the intervention group versus the control group assessed using metagenomics
Difference in average infant daily crying duration
Difference in average infant daily crying duration at the end of the intervention in the IG versus the CG assessed using a structured infant crying and fussing diary.
Difference in average infant daily fussing duration
Difference in average infant daily fussing duration at the end of the intervention in the IG versus the CG assessed using a structured infant crying and fussing diary.
Difference in average infant daily crying and fussing duration in the IG
Difference in average infant daily crying duration and fussing duration combined from baseline (V1) to intervention end (V4) in the IG assessed using a structured infant crying and fussing diary.
Difference in average infant daily crying duration in the Intervention group
Difference in average infant daily crying duration from baseline (V1) to intervention end (V4) in the Intervention group assessed using a structured infant crying and fussing diary.
Difference in average infant daily fussing duration in the Intervention group
Difference in average infant daily fussing duration from baseline (V1) to intervention end (V4) in the interventional group assessed using a structured infant crying and fussing diary.
Infant daily crying and fussing duration assessed longitudinally
Infant daily crying and fussing duration combined assessed longitudinally across the intervention assessed using a structured infant crying and fussing diary.
Infant crying/fussing per 24 hours
Episodes of infant crying/fussing per 24 hours assessed using a structured infant crying and fussing diary.
Percentage of children achieving a reduction in daily crying and fussing
Percentage of children achieving a reduction in daily crying, fussing, crying and fussing time combined of ≤ 25 % and ≤ 50 % assessed using a structured infant crying and fussing diary.
Incidence of infantile colic
Incidence of infantile colic assessed using a structured infant crying and fussing diary.
Parental perception of colic severity
Parental perception of colic severity assessed using a 10-cm visual analog scale (VAS)
Overall GI tolerance and individual GI symptoms
Overall infant GI tolerance and individual GI and GI-related symptoms (stooling, spitup/ vomiting, gassiness, crying, fussiness) assessed using IGSQ-13
Overall GI tolerance and individual GI symptoms
Change in IGSQ-13 scores assessed using IGSQ-13
Overall GI tolerance and individual GI symptoms
Functional GI symptoms (regurgitation, consistency of stools), crying, allergic symptoms (atopic eczema) and respiratory symptoms assessed using CoMiSS
Overall GI tolerance and individual GI symptoms
Change in CoMiSS scores assessed using CoMiSS
Overall GI tolerance and individual GI symptoms
Stool consistency, spitting up/vomiting and flatulence assessed using 1-day retrospective GI diary at V1 (day 0) and prospective 3-Day GI symptom diary diaries at home (H2, H3 and H4) just prior to V2 (day 7), V3 (day 14) and V4 (day 21)
Infant sleep
Infant sleep duration and nighttime wakings per 24 hours assessed using Brief infant sleep questionnaire (BISQ)
Infant Quality of life
Infant quality of life assessed using an Infant Quality of Life instrument. The tool includes IQI includes questions on 7 health items such as sleeping, crying, feeding , skin, breathing, playfulness and Interaction, and stooling. Each item consists of 4 levels, most of which are ranked by severity.
Parental and family quality of life
Parental/family quality of life will be assessed using a Quality of Life Visual Analog Scale that rates the parent / family's quality of life based on a 10-point Likert scale.
Infant fecal gut microbiota
Microbiome of fecal samples to investigate the communities of microbes, their taxonomy, strain composition, diversity, ecology, functionalities, and the metabolites produced assessed using metagenomics.
Fecal metabolism
Fecal metabolism (pH, organic acids)
Fecal markers of inflammation calprotectin
Inflammation biomarkers calprotectin assessed using ELISA.
Fecal markers of inflammation lipocalin
Inflammation biomarkers lipocalin assessed using ELISA.
Infant anthropometry weight
Weight in grams
Infant anthropometry length
Length in cm
Infant anthropometry head circumference
Head circumference in cm
Infant anthropometry weight gain
Weight gain in g/d
Infant anthropometry length gain
Length gain in cm/d
Infant illness and infection and medication usage
Data collected using a calendar-based electronic Infant Illness Diary (IID)

Full Information

First Posted
March 28, 2022
Last Updated
October 2, 2023
Sponsor
Société des Produits Nestlé (SPN)
search

1. Study Identification

Unique Protocol Identification Number
NCT05554991
Brief Title
Human Milk Oligosaccharide (HMO) Supplementation in Colic Management
Official Title
Efficacy and Tolerability of a Composition Comprising of HMO in a Supplement Format on Colic Management: a Double-blind, Randomized, Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 24, 2022 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Société des Produits Nestlé (SPN)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Efficacy and tolerability of a composition comprising of HMO in a supplement format on colic management: a double-blind, randomized, placebo-controlled trial
Detailed Description
This is a double-blinded, randomized, placebo-controlled trial. The purpose of this trial is to investigate the efficacy and tolerability of a composition comprising of HMO in a supplement format in the management of colicky infants aged 2-12 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colic

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double-blinded, placebo-controlled, parallel-arm, intervention study
Masking
ParticipantInvestigator
Masking Description
Randomization will be carried out using iMedidata Randomization Trial Supply Management System with the dynamic allocation algorithm.
Allocation
Randomized
Enrollment
144 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Liquid oral supplement comprising HMO
Arm Type
Experimental
Arm Description
2 ampules/day for 21 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
2 ampules/day for 21 days
Intervention Type
Dietary Supplement
Intervention Name(s)
HMO
Intervention Description
Composition comprising of HMO
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Placebo supplementation having the same appearance and dosing regimen as the intervention
Intervention Type
Behavioral
Intervention Name(s)
Parental reassurance and support
Intervention Description
Both groups will receive standardized written materials to provide parental reassurance and support, in alignment with local clinical practice
Primary Outcome Measure Information:
Title
Difference in average infant daily crying and fussing duration
Description
Difference in average infant daily crying and fussing duration at the end of the intervention in the Intervention Group (IG) versus the Control Group (CG). The crying and fussing duration is measured using a structured infant crying and fussing diary.
Time Frame
At the end of the intervention period (day 21)
Secondary Outcome Measure Information:
Title
Modulation of infant gut microbiota (communities of microbes, their taxonomy, strain composition, diversity, ecology, functionalities, and the metabolites produced)
Description
Modulation of infant gut microbiota in the intervention group versus the control group assessed using metagenomics
Time Frame
V1 (day 0), V2 (day 7), and V4 (day 21)
Title
Difference in average infant daily crying duration
Description
Difference in average infant daily crying duration at the end of the intervention in the IG versus the CG assessed using a structured infant crying and fussing diary.
Time Frame
Change from baseline (V1) to intervention end (V4)
Title
Difference in average infant daily fussing duration
Description
Difference in average infant daily fussing duration at the end of the intervention in the IG versus the CG assessed using a structured infant crying and fussing diary.
Time Frame
Change from baseline (V1) to intervention end (V4)
Title
Difference in average infant daily crying and fussing duration in the IG
Description
Difference in average infant daily crying duration and fussing duration combined from baseline (V1) to intervention end (V4) in the IG assessed using a structured infant crying and fussing diary.
Time Frame
Change from baseline (V1) to intervention end (V4)
Title
Difference in average infant daily crying duration in the Intervention group
Description
Difference in average infant daily crying duration from baseline (V1) to intervention end (V4) in the Intervention group assessed using a structured infant crying and fussing diary.
Time Frame
Change from baseline (V1) to intervention end (V4)
Title
Difference in average infant daily fussing duration in the Intervention group
Description
Difference in average infant daily fussing duration from baseline (V1) to intervention end (V4) in the interventional group assessed using a structured infant crying and fussing diary.
Time Frame
Change from baseline (V1) to intervention end (V4)
Title
Infant daily crying and fussing duration assessed longitudinally
Description
Infant daily crying and fussing duration combined assessed longitudinally across the intervention assessed using a structured infant crying and fussing diary.
Time Frame
Longitudinal changes across specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Infant crying/fussing per 24 hours
Description
Episodes of infant crying/fussing per 24 hours assessed using a structured infant crying and fussing diary.
Time Frame
At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Percentage of children achieving a reduction in daily crying and fussing
Description
Percentage of children achieving a reduction in daily crying, fussing, crying and fussing time combined of ≤ 25 % and ≤ 50 % assessed using a structured infant crying and fussing diary.
Time Frame
At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Incidence of infantile colic
Description
Incidence of infantile colic assessed using a structured infant crying and fussing diary.
Time Frame
At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Parental perception of colic severity
Description
Parental perception of colic severity assessed using a 10-cm visual analog scale (VAS)
Time Frame
At specific visits V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Overall GI tolerance and individual GI symptoms
Description
Overall infant GI tolerance and individual GI and GI-related symptoms (stooling, spitup/ vomiting, gassiness, crying, fussiness) assessed using IGSQ-13
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Overall GI tolerance and individual GI symptoms
Description
Change in IGSQ-13 scores assessed using IGSQ-13
Time Frame
Baseline to intervention end (day 21)
Title
Overall GI tolerance and individual GI symptoms
Description
Functional GI symptoms (regurgitation, consistency of stools), crying, allergic symptoms (atopic eczema) and respiratory symptoms assessed using CoMiSS
Time Frame
At V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Overall GI tolerance and individual GI symptoms
Description
Change in CoMiSS scores assessed using CoMiSS
Time Frame
From baseline to intervention end (day 21)
Title
Overall GI tolerance and individual GI symptoms
Description
Stool consistency, spitting up/vomiting and flatulence assessed using 1-day retrospective GI diary at V1 (day 0) and prospective 3-Day GI symptom diary diaries at home (H2, H3 and H4) just prior to V2 (day 7), V3 (day 14) and V4 (day 21)
Time Frame
1-day retrospective GI diary at V1 (day 0) and prospective 3-Day GI symptom diary diaries at home (H2, H3 and H4) just prior to V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Infant sleep
Description
Infant sleep duration and nighttime wakings per 24 hours assessed using Brief infant sleep questionnaire (BISQ)
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Infant Quality of life
Description
Infant quality of life assessed using an Infant Quality of Life instrument. The tool includes IQI includes questions on 7 health items such as sleeping, crying, feeding , skin, breathing, playfulness and Interaction, and stooling. Each item consists of 4 levels, most of which are ranked by severity.
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Parental and family quality of life
Description
Parental/family quality of life will be assessed using a Quality of Life Visual Analog Scale that rates the parent / family's quality of life based on a 10-point Likert scale.
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Infant fecal gut microbiota
Description
Microbiome of fecal samples to investigate the communities of microbes, their taxonomy, strain composition, diversity, ecology, functionalities, and the metabolites produced assessed using metagenomics.
Time Frame
V1 (day 0), V2 (day 7), and V4 (day 21)
Title
Fecal metabolism
Description
Fecal metabolism (pH, organic acids)
Time Frame
V1 (day 0), V2 (day 7), and V4 (day 21)
Title
Fecal markers of inflammation calprotectin
Description
Inflammation biomarkers calprotectin assessed using ELISA.
Time Frame
V1 (day 0) and V4 (day 21)
Title
Fecal markers of inflammation lipocalin
Description
Inflammation biomarkers lipocalin assessed using ELISA.
Time Frame
V1 (day 0) and V4 (day 21)
Title
Infant anthropometry weight
Description
Weight in grams
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21)
Title
Infant anthropometry length
Description
Length in cm
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21)
Title
Infant anthropometry head circumference
Description
Head circumference in cm
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21)
Title
Infant anthropometry weight gain
Description
Weight gain in g/d
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21)
Title
Infant anthropometry length gain
Description
Length gain in cm/d
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) (optional if V3 is a phone call) and V4 (day 21)
Title
Infant illness and infection and medication usage
Description
Data collected using a calendar-based electronic Infant Illness Diary (IID)
Time Frame
V1 (day 0) until V4 (day 21)
Other Pre-specified Outcome Measures:
Title
Duration and number of episodes of infant crying type based on a crying-type classification of the audio recording
Description
Duration and number of episodes of each infant crying type (pain, fussiness, hunger) based on a crying-type classification of the audio recording
Time Frame
24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21)
Title
Proportion of children with a specific crying type based on a crying-type classification of the audio recording
Description
Proportion of children with a specific crying type (pain, fussiness, hunger) based on a crying-type classification of the audio recording
Time Frame
24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21)
Title
Duration of crying based on a crying-type classification of the audio recording
Description
Duration of crying based on a crying-type classification of the audio recording
Time Frame
24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21)
Title
Duration of fussing based on a crying-type classification of the audio recording
Description
Duration of fussing based on a crying-type classification of the audio recording
Time Frame
24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21)
Title
Duration of crying and fussing combined based on a crying-type classification of the audio recording
Description
Duration of crying and fussing combined based on a crying-type classification of the audio recording
Time Frame
24 hours after V1 (day 0), V2 (day 7), V3 (day 14) and for 3 days prior to V4 (day 21)
Title
Crying and fussing comparison between the structured infant crying and fussing diary and the crying-type classification of the recording of infant crying/fussing across the intervention
Description
Infant daily crying and fussing duration compared between the structured infant crying and fussing diary and the crying-type classification of the recording of infant crying/fussing across the intervention
Time Frame
V1 (day 0), V2 (day 7), V3 (day 14) and V4 (day 21)
Title
Maternal Postpartum depression/ anxiety
Description
Maternal postpartum depressive and anxiety symptoms assessed using an Edinburgh postnatal depression scale (EPDS)
Time Frame
V1 (day 0) and V4 (day 21)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Weeks
Maximum Age & Unit of Time
12 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Infants 2 weeks - 12 weeks of age at enrolment Infants diagnosed with colic according to Rome IV criteria: Diagnostic criteria for research purposes (infant must meet all Rome IV criteria): An infant who is less than 5 months of age (in the current clinical trial, only infants 2 weeks to 8 weeks of age will be enrolled) when the symptoms start and stop Recurrent and prolonged periods of infant crying, fussing, or irritability reported by caregivers that occur without obvious cause and cannot be prevented or resolved by caregivers No evidence of infant failure to thrive, fever, or illness Excessive crying/fussiness for 3 or more hours per day during 3 or more days in the past 7 days as reported by parents to the clinician Total 24-hour crying plus fussing is 3 hours or more when measured by at least one prospectively kept 24-hour behavior diary. (The Structured Infant Crying and Fussing Diary will be dispensed at the screening visit (V0), completed for two 24-hour periods at H0 (days -3 to -1), and returned at V1 to be used as part of the diagnostic criteria for infantile colic.) Term infants (≥ 37 weeks) generally healthy with normal birth weight (≥2.5kg) and singleton born Predominantly formula fed* (formula fed ≥ 80% of the time) for at least 7 days before randomization and the choice of formula feeding has been made by the parents before the beginning of the trial. Infants who have been on the same formula for the past 5 days Signed informed consent obtained for infant's and parents'/Legally Acceptable Representative (LAR) participation in the study Parent/LAR of infant agrees not to enroll infant in another interventional clinical research study while participating in this study Parent of the infant/LAR is willing and able to fulfill the requirements of the study protocol Parent of infant can be contacted throughout the study Predominantly formula feeding defined in the study means that the infant's predominant source of nourishment is formula. Specifically, infants are fed with formula for at least 80% of total milk feeds per day. Exclusion criteria: Presence of any congenital condition and/or previous or current illness/infection and (or) medication use that could interfere with the main study outcomes. Clinical evidence of chronic illness or gastrointestinal disorders, major medical problems (e.g. ill, immunocompromised, major developmental or genetic abnormality). Known cow's milk protein allergy, lactose intolerance, or galactosaemia; including presence of any allergic manifestations. Received any special formula (e.g. lactose-free, hydrolyzed protein) within 5 days before randomization or switched formulas within 5 days before randomization. Received any of the following products/medication within 5 days before randomization: Antibiotics Alginate Prokinetics Proton pump inhibitors Simethicone L. reuteri probiotic Formula containing Human milk Oligosaccharides Other infant(s) <6months of age living in the same household. Current participation in another interventional clinical trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cecilia L Fumero, PhD
Phone
+41 21 785 8328
Email
CECILIA.FUMERO@RDLS.NESTLE.COM
Facility Information:
Facility Name
Ospedale Pediatrico Giovanni XXIII, Policlinico di Bari
City
Bari
ZIP/Postal Code
70126
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruggiero Francavilla, MD, PhD
Facility Name
ASST FBF Sacco
City
Milano
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elvira Verduci, MD.
Facility Name
AOUP Paolo Giaccone
City
Palermo
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuffrè P Mario, MD.
Facility Name
Azienda Ospedaliero -Universitaria Pisana
City
Pisa
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diego Perioni, MD.
Facility Name
Centro de Salud El Ranero
City
Murcia
ZIP/Postal Code
30009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio Iofrío De Arce, Dr.
Facility Name
Hospital Clínico Universitario de Santiago de Compostela
City
Santiago de Compostela
ZIP/Postal Code
15706
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Rosaura Leis Trabazo, Dr.
Facility Name
Unidad de Estudios e Investigación IHP
City
Sevilla
ZIP/Postal Code
41014
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ignacio Salamanca, Dr.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Human Milk Oligosaccharide (HMO) Supplementation in Colic Management

We'll reach out to this number within 24 hrs